Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
STAT+
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Politics
STAT+

Two key FDA officials to retire, leaving three divisions without permanent leaders

By Ike Swetlitz April 26, 2018

Reprints
FDA campus
Andrew Harnik/AP

WASHINGTON — Two Food and Drug Administration directors will retire this week, according to the agency.

The departures leave three of the FDA’s 19 drug review divisions without permanent leaders.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Ike Swetlitz

Washington Correspondent

Ike is a Washington correspondent, reporting at the intersection of life science and national politics.

Tags

Dutch health minister won’t cover a Gilead cancer drug…
Dutch health minister won’t cover a Gilead cancer drug due to the cost
Under pressure, biotech and pharma grapple with how to…
Under pressure, biotech and pharma grapple with how to take climate action
Combination of two drugs can help treat methamphetamine addiction…
Combination of two drugs can help treat methamphetamine addiction for some, new clinical trial data shows 
Solicitor general urges Supreme Court to review ‘skinny labeling’…
Solicitor general urges Supreme Court to review ‘skinny labeling’ and generic drug access
Drug middlemen switch tactics, but the outcome is the…
Drug middlemen switch tactics, but the outcome is the same: high prices
FDA proposes a new plan to streamline updates to…
FDA proposes a new plan to streamline updates to medical devices that use AI

Recommended Stories